{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:18Z","timestamp":1787010138316,"version":"build-2736575974"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Cytokine release syndrome (CRS) is an immune hyperactivation phenomenon in immunotherapy and, unlike other immune-related adverse events, only a few case reports have documented CRS due to the use of immune checkpoint inhibitors. In this article, we report a case of 2 episodes of CRS and delirium caused by pembrolizumab in a short period of time. This helps clinicians to understand CRS and to improve the diagnosis and treatment of immune-related adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 67-year-old patient with lung cancer developed fever, delirium, acute renal insufficiency, and acute cardiac insufficiency after 9 cycles of pablizumab therapy, and reappeared with these symptoms 1 week after improvement with glucocorticoid therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>The patient presented with concomitant cardiac insufficiency, hepatic and renal failure, delirium with high C-reactive protein levels and the patient\u2019s response to glucocorticoids, and exclusion of cerebrovascular accident and severe infection, resulting in a final diagnosis of CRS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Glucocorticoid therapy and symptomatic support treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>After 2 hospitalizations, the patient did not develop CRS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>To our knowledge, this is the first case of delirium and CRS that occurred twice in a short period of time. This patient had no immune-related adverse reactions during the previous 9 immunotherapy sessions. This adverse reaction occurred after the inflammation of the wisdom teeth and was presumed to be related to an overstimulation of the immune response due to infection. Premature discontinuation of hormones for the patient\u2019s 1st treatment of CRS may be the reason for the 2nd occurrence of CRS. Therefore, timely and full course of glucocorticosteroids is a key therapeutic measure to cause CRS after the use of immune checkpoint inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000031998","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T15:17:11Z","timestamp":1673536631000},"page":"e31998","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Cytokine release syndrome induced by pembrolizumab: A case report"],"prefix":"10.1097","volume":"101","author":[{"given":"Xinyu","family":"Zhang","sequence":"first","affiliation":[{"name":"Shandong University of Traditional Chinese Medicine, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Fu","sequence":"additional","affiliation":[{"name":"Shandong University of Traditional Chinese Medicine, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4298-9457","authenticated-orcid":false,"given":"Chaoguang","family":"Yan","sequence":"additional","affiliation":[{"name":"Weifang Hospital of Traditional Chinese Medicine, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade.","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome.","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1097\/MPH.0000000000000703","article-title":"Nivolumab in the treatment of refractory pediatric hodgkin lymphoma.","volume":"39","author":"Foran","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2217\/imt-2016-0134","article-title":"Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab.","volume":"9","author":"Rassy","year":"2017","journal-title":"Immunotherapy"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"e26642","DOI":"10.1002\/pbc.26642","article-title":"Severe cytokine release syndrome in a patient receiving PD-1-directed therapy.","volume":"64","author":"Rotz","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2217\/imt-2018-0025","article-title":"Nivolumab-induced cytokine-release syndrome in relapsed\/refractory Hodgkin\u2019s lymphoma: a case report and literature review.","volume":"10","author":"Zhao","year":"2018","journal-title":"Immunotherapy"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/CJI.0000000000000236","article-title":"Cytokine release syndrome during sequential treatment with immune checkpoint inhibitors and kinase inhibitors for metastatic melanoma.","volume":"42","author":"Dimitriou","year":"2019","journal-title":"J Immunother"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40425-019-0582-4","article-title":"Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report.","volume":"7","author":"Honjo","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.jtho.2018.11.025","article-title":"Cytokine release syndrome with pseudoprogression in a patient with advanced non-small cell lung cancer treated with pembrolizumab.","volume":"14","author":"Kogure","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00134-017-4943-5","article-title":"Understanding cytokine release syndrome.","volume":"44","author":"G\u00f6del","year":"2018","journal-title":"Intensive Care Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome.","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0049-0172(90)90055-K","article-title":"Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen.","volume":"20","author":"Schultz","year":"1990","journal-title":"Semin Arthritis Rheum"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031998","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:48:15Z","timestamp":1746319695000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":13,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000031998","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]}}}